title: [Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review].
abstract: Philadelphia or BCR-ABL positive acute lymphoblastic leukemia (PH+ ALL) is the most common and severe of adult ALL. The only potentially curator treatment remains allogeneic hematopoietic stem cells transplantation (SCT) in first complete remission. The use of imatinib has revolutionized the treatment of chronic myeloid leukemia. Its incorporation into PH + ALL protocols also improved the prognosis of this disease giving better complete remission rates compared to chemotherapy alone. The treatment of patients not eligible for SCT remains controversial. Prolonged use of high dose tyrosine kinase inhibitors (TKI) (ie: imatinib at 600 or 800 mg/j) as maintenance therapy seems to be a reasonable approach. We present a case of prolonged molecular remission of PH+ ALL under TKI alone as maintenance therapy.
authors.affiliation: Service d'hématologie clinique, Hôpital militaire d'instruction Mohamed V, Rabat, Maroc.
authors.forename: Abderrahim
authors.initials: A
authors.lastname: Raissi
authors.affiliation: Service d'hématologie clinique, Hôpital militaire d'instruction Mohamed V, Rabat, Maroc.
authors.forename: Majdouline
authors.initials: M
authors.lastname: Bouaouad
authors.affiliation: Service d'hématologie clinique, Hôpital militaire d'instruction Mohamed V, Rabat, Maroc.
authors.forename: Noufissa Alami
authors.initials: NA
authors.lastname: Drideb
authors.affiliation: Service d'hématologie clinique, Hôpital militaire d'instruction Mohamed V, Rabat, Maroc.
authors.forename: Selim
authors.initials: S
authors.lastname: Jennane
authors.affiliation: Service d'hématologie clinique, Hôpital militaire d'instruction Mohamed V, Rabat, Maroc.
authors.forename: El Mahdi
authors.initials: el M
authors.lastname: Mahtat
authors.affiliation: Service d'hématologie clinique, Hôpital militaire d'instruction Mohamed V, Rabat, Maroc.
authors.forename: Kamal
authors.initials: K
authors.lastname: Doghmi
authors.affiliation: Service d'hématologie clinique, Hôpital militaire d'instruction Mohamed V, Rabat, Maroc.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Mikdame
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000627:therapeutic use*; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D012074:Remission Induction; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide
keywords: Bcr-Abl + ALL; hematopoetic stem cell transplantation; prolonged molecular remission